👋 Hey, let’s get into it. Bristol Myers Squibb is apparently done treating AI like the intern sitting quietly in the corner taking notes.

The company just handed Anthropic's Claude access to more than 30,000 employees and plans to weave agentic AI directly into drug discovery, manufacturing, and commercial operations. Early pharma AI efforts often looked like expensive chatbots wearing lab coats. BMS is aiming for something much bigger.

The goal is ambitious: cut the time from target identification to lead molecule discovery in half. Pharma used to compete over pipelines. Now they may start competing over which algorithm gets office keys first.

😬 $2.5B Antitrust Case Hangs Over Takeda
Takeda just received a very expensive reminder that legal risks can compound faster than interest rates. A federal jury ruled the company liable in a landmark pay-for-delay antitrust case involving constipation drug Amitiza and awarded $885 million in damages. Under antitrust rules, those damages could automatically triple to roughly $2.5 billion once judgment is entered. Pharmacies, insurers, retailers and health funds alleged Takeda conspired to delay generic competition and keep prices elevated. Takeda says it plans to vigorously appeal, but either way this case may become a legal textbook example for future challenges.

🛒 Lilly's Shopping Spree Keeps Rolling
Most companies would slow down after an acquisition spree worth billions. Not Lilly. The company is acquiring Engage Biologics for $202 million as it continues using GLP-1 money to expand its innovation footprint. Engage's Tethosome platform focuses on non-viral DNA delivery systems designed to improve potency, tolerability, and repeat dosing challenges. Lilly executives previously said they wanted to become the backbone of global innovation. Judging by recent activity, they seem determined to buy enough pieces to build the whole skeleton.

⚠️ FDA Flags GLP-1 Supplier Over Semaglutide Imports
The FDA handed a warning letter to a Chinese supplier after investigators found semaglutide shipments tied to a manufacturing site not authorized under new import rules. Inspectors say the company relabeled ingredients in ways that may have bypassed safeguards designed to protect patients from unverified sources. The restrictions were introduced to control growing concerns around foreign GLP-1 ingredients entering the U.S. market. The FDA created a "green list" system specifically to avoid this situation. Someone apparently treated it more like a suggestion than a rulebook.

🏛️ Trump Bought Up to $680K of Lilly Stock During GLP-1 Tailwinds
President Donald Trump disclosed stock purchases totaling as much as $680,000 in Eli Lilly earlier this year, and the timing is already drawing attention. The purchases coincided with several policy developments that benefited Lilly's obesity business, including movement toward Medicare reimbursement for weight-loss drugs. Disclosure forms show seven separate Lilly purchases between January and March. The Trump Organization says investments are handled by independent brokers, but the overlap between stock activity and favorable policy developments is predictably creating fresh ethics questions.

🤖 Incyte Expands AI Partnership With $80M Upfront Deal
Incyte expanded its Genesis partnership with an $80 million upfront payment and potential milestones exceeding $1 billion across multiple AI-driven drug discovery programs.

🏭 Gilead Signs $140M Korea Manufacturing Deal
Gilead signed a new $140 million API supply agreement with Yuhan, extending a manufacturing relationship that now spans four separate deals.

📉 BioMarin's $270M Rare Disease Acquisition Hits Trouble
BioMarin's $270 million Inozyme acquisition faces new uncertainty after its lead enzyme replacement therapy missed a key phase 3 endpoint.

🥊 UCB's Bimzelx Beats Skyrizi in Phase 3 Trial
UCB's Bimzelx outperformed AbbVie's Skyrizi on joint outcomes in a head-to-head phase 3 psoriatic arthritis study.

📈 Regeneron Partnership Pushes Parabilis Toward IPO
Parabilis appears to be moving closer to public markets after recently securing a tumor-focused partnership agreement with Regeneron.

🎯 Merck's ADC Candidate Improves Survival Outcomes
Merck's Kelun-derived antibody drug conjugate delivered improved survival metrics in patients with late-stage endometrial cancer during testing.

⚖️ Supreme Court Rejects Medicare Drug Pricing Challenges
Drugmakers suffered another setback after the Supreme Court declined to hear multiple legal challenges targeting Medicare drug price negotiations.

You probably expected Lilly versus Novo. Maybe Lilly versus regulators. Possibly Lilly versus PBMs. Instead, this week's unexpected matchup looks like a screenwriter with too much coffee pitched: “Hear me out... Big Pharma vs. Big Religion. Plot twist: pharma is the good guy.”

Lilly filed a 66-page lawsuit alleging a long-running rebate fraud scheme involving Trulicity that it says siphoned more than $200 million. According to the complaint, a mail-order pharmacy called DrugPlace purchased large quantities of Trulicity through authorized distributors while claiming the drugs served members of a church-affiliated health program. Lilly alleges the drugs were instead sold on secondary markets while rebate claims kept flowing.

The lawsuit also pulls church leadership into the story. Lilly alleges several bishops and a leader within the Church of God in Christ, a major Pentecostal denomination, played roles in the alleged scheme. The church itself is not named as a defendant.

The company says the numbers eventually stopped making sense. Nearly every prescription allegedly reflected the same quantity and duration, almost no refills occurred, and rebate claims involved only Trulicity rather than a realistic mix of medications. Lilly also says enrollment claims appeared inflated. DrugPlace allegedly cited roughly seven million church members despite survey estimates putting total church membership much lower.

Lilly says the activity stretched across at least six years before internal data analysis uncovered unusual patterns. The company also claims other pharmaceutical manufacturers may have been affected.

The entire thing feels bizarre because it combines churches, bishops, PBMs, diabetes drugs, rebate structures and alleged fraud into one story. On the bright side, at least pharma isn’t the villain in this story.

This is the ratio between Johnson & Johnson CEO Joaquin Duato's compensation and the company's median employee pay. Duato earned $32.6 million last year while the median employee made roughly $91,000. Lilly and Pfizer CEO’s were not far behind. Apparently one of pharma's most scalable products continues to be executive compensation.

Here’s what biotech Redditors are talking about:

🤥 Antibody Trust Issues Thanks to Thermo Fisher
Redditors in r/labrats spent the week spiraling after users highlighted what appeared to be manipulated western blot images associated with ThermoFisher antibodies. The discussion quickly shifted from one image to broader frustrations around antibody quality. Multiple users argued that in-house validation is practically mandatory because too many products arrive with questionable performance. The most upvoted reactions were somewhere between scientific criticism and emotional damage.

😬 Week Two at Your New Job...Okay to Interview Somewhere Else?
One biotech worker had just started a new job and, during only their second week, got contacted about what looked like an even better opportunity. Their question wasn't whether they should quit, it was whether it's okay to take an interview that soon after starting somewhere new. The debate split into familiar camps. Some argued biotech is small and burned bridges can matter more than salary jumps. Others took a much simpler approach: put yourself first and take the interview. The practical discussion quickly shifted to logistics: how exactly do you ask for time off in week two without raising eyebrows... surprise doctor appointment, anyone?

💊 TrumpRx Adds 600+ Generic Drugs to Affordability Push
The White House expanded TrumpRx with more than 600 generic medicines as pressure around prescription affordability continues building.

🤖 AI May Scale Trial Flaws
New analysis found only 29.3% of trial protocols align with patient outcomes, raising concerns that AI could rapidly amplify flawed design decisions.

🌍 Roche Opens Xofluza Access Across 129 Countries
Roche signed a licensing deal allowing generic versions of its flu treatment Xofluza to reach 129 developing countries.

💻 Blank Bio Trains AI on RNA's Hidden Language
Blank Bio just raised $7.2 million to build foundation models focused on RNA biology and patient-level tumor prediction. The company's premise is that traditional RNA analyses throw away enormous amounts of information by reducing complex transcriptomic signals into simplified summaries. Through a strategic collaboration with PacBio, Blank plans to generate long-read sequencing data to train its models further. The company wants to help identify patient populations, improve biomarker discovery, and refine clinical predictions. AI increasingly wants into biotech's basement where all the messy biology lives.

🧬 May 21, 2008 — Genetic Privacy Gets a Seat at the Table
On this day in 2008, President George W. Bush signed the Genetic Information Nondiscrimination Act (GINA) into law. The legislation protects people from discrimination based on genetic information in health insurance and employment decisions. It arrived years before consumer DNA kits became mainstream and long before today's explosion of genomic data. Supporters saw the issue early: people would be a lot less eager to learn what their genes revealed if employers or insurers could use that information against them.

J&J's CEO made 358 times more than the company's median employee, which sounds enormous until you look at Wayfair CEO Niraj Shah pulling in a reported $280.8 million. J&J's CEO earned $32.6 million. Shah basically looked at pharma compensation and said, "that's cute." Apparently curing diseases is nice, but drop-shipping couches may still be where the real money is hiding.

That’s all for today. See you Tuesday for the next issue. 👋

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead